adMare
News
August 25 2023
Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.
August 15 2023
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
August 10 2023
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
July 24 2023
Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.
June 29 2023
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies
June 15 2023
Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023
June 08 2023
Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec
June 05 2023
Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities
May 22 2023
Inversago Pharma Announces New Data to be Presented at the 2023 American Thoracic Society International Conference
April 20 2023
Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
April 19 2023
ZONE study to assess ZT-01’s ability to prevent night-time hypoglycemia, a condition for which there are currently no available therapies
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall, 4th Floor
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
T. 514.375.3334
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 405
Toronto, Ontario, Canada
M5G 1M1
